#MedNews - The prevalence of alcohol-related liver disease and metabolic dysfunction-associated alcohol-related liver disease has been underestimated in the USA.
Full story 👉 buff.ly/HchfIrq
#HepSky #MetALD #ALD
🆕 The burden of chronic hepatitis B and C in 2022 and progress towards elimination: a global report
www.thelancet.com/journals/lan...
#LiverSky #IDSky #HepSky #MedSky
New research - Natural history of chronic hepatitis B in untreated adults without cirrhosis according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review & meta-analysis
www.thelancet.com/journals/lan...
#LiverSky #MedSky #IDSky #HepSky
New research - Efficacy of antiviral therapy in adults with chronic hepatitis B according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis
www.thelancet.com/journals/lan...
#LiverSky #MedSky #IDSky #HepSky
#MASLD and #HBV overlap tackled in this article - lots of questions remaining in how to assess and treat this emerging dual threat to global #liver health 🧪
#MedSKy #LiverSky #HepSky #hepatitis
hepatologyforum.org/article/257
It looked like another leisurely Expo for new TAFE students to learn about health, services etc... so what brought that smile of pure delight to educator Yingbin's face? @hepatitisaustralia.bsky.social #Hepsky
#MedNews - The FGF21 analog efimosfermin alfa significantly improves fibrosis regression and is well tolerated in people with #MASH and moderate or advanced fibrosis.
Full story 👉 buff.ly/zxlbNW7
#GastroSky #HepSky
New World Report in @thelancet.com examines the controversial trial of hepatitis B virus birth dose vaccination that was planned in Guinea-Bissau
#HepSky #LiverSky #IDSky
Fig. 1: Diagram illustrating the risk of hepatocellular carcinoma attributable to chronic hepatitis B infection and strategies to mitigate it.
FEBRUARY ISSUE | YEAR IN REVIEW: Viral hepatitis in 2025 "Novel insights into chronic HBV infection"
www.nature.com/articles/s41...
#Hepsky #Liversky
Guinea-Bissau Suspends Trump-Backed Hep B Vaccine Trial for Ethical Review www.medpagetoday.com/infectiousdi...
#LiverSky #IDSky #HepSky #MedSky
#MedNews - Adolescent patients receiving a #LiverTransplant from an age-mismatched donor are less likely to have their graft survive beyond 10 years than those with an age-matched donor.
Full story 👉 buff.ly/BKh0kLy
#HepSky #PediatricMed
New research - ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial
www.thelancet.com/journals/lan...
#HepSky #IDSky #LiverSky #MedSky
Viral #hepatitis poses unique challenges in people living with #HIV.
Examine the epidemiology, immune considerations, vaccination strategies, and treatment approaches for HAV-HEV among people living with HIV.
👉 buff.ly/8R72RD5
#HepSky #IDSky
RESEARCH HIGHLIGHT "SOLSTICE: tobevibart plus elebsiran for hepatitis D"
JANUARY ISSUE | RESEARCH HIGHLIGHT "SOLSTICE: tobevibart plus elebsiran for hepatitis D"
www.nature.com/articles/s41...
#Hepsky #IDsky #Liversky
As 2025 draws to a close, here's a taste of the #Gastroenterology and #Hepatology content from Springer Medicine that got your attention this year.
#GastroSky #HepSky
New Editorial - ACIP’s HBV birth-dose vaccine recommendations: a fiasco
www.thelancet.com/journals/lan...
#HepSky #LiverSky #MedSky #IDSky
Evaluate the role of non-invasive magnetic resonance biomarkers in assessing the key features of #MASLD–steatosis, steatohepatitis, and fibrosis–and their potential to reduce reliance on liver biopsy in clinical practice.
👉 buff.ly/ZQ0bNIW
#HepSky
Picture of mug with big text Vaccines cause adults’
It’s a crucial moment to say this again, loudly:
#vaccines cause adults.
Let’s keep causing adults.
🧪 #HBV #NoHep #vaccineswork #MedSky #HepSky #IDSky #PublicHealth @who.int
@gavi.org @altcdc.altgov.info @worldhepalliance.bsky.social
#MedNews - #Pemvidutide improves symptoms of metabolic dysfunction-associated steatohepatitis after 24 weeks of treatment, the IMPACT trial suggests.
Full story 👉 buff.ly/Ai3eet2
#HepSky #MASH
❗ LAST CHANCE TO REGISTER❗
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
With #AASLD2025 coming to a close, continue your learning on #ALD with our upcoming free webinar.
Find out more about advances in treatment and what you need to know about the introduction of #MetALD as a new category of liver disease.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
Combination therapies involving novel drugs hold promise for improving chronic #HepB outcomes, particularly in achieving a functional cure.
What are these novel drugs and how might they be combined to improve efficacy?
👉 buff.ly/fM692O1
#IDSky #HepSky
Keynote webinar | Spotlight on addressing alcohol-associated liver disease
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now: bit.ly/3Jmukor. #HepSky #MedSky
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now 👉 buff.ly/zHkugyV
#HepSky #MedSky
💬 Proud to be featured by #CORDIS! They spotlight #TherVacB's clinical trial as a key step toward a functional cure for chronic #hepB.
🎥 Our awareness videos with @dsolve.bsky.social explain diagnosis, co-infection & care.
🔗 link.europa.eu/QMFx3J
#HBV #HDV #LiverSky #HepSky #LiverTwitter
🎉 The #TherVacB Project is now on LinkedIn! Follow us: www.linkedin.com/company/ther...
🧵Our 1st post sets the scene: the global challenge of chronic #HepatitisB and our goal of a #therapeutic #vaccine: tinyurl.com/TherVacB-Lin...
#HBV #H2020 #HealthInnovation #TherVacB #HepSky #LiverSky
All opportunities to develop and share robust evidence to help us enhance progress towards #elimination of viral #hepatitis should be welcomed! Note special issue of #BMCInfectiousDiseases planned for 2026.
#HepSky #MedSky #GastroSky #IDSky 🧪
Great to collaborate with colleagues in Ethiopia. A decentralised HBV programme achieved some good on-treatment results but half of patients lost to follow up. We need to work out how to better engage and retain patients in care. #idsky #hepsky
www.thelancet.com/journals/lan...
Published today. We found that hepatitis B was the leading cause of cirrhosis and HCC in southern Malawi. HCC is diagnosed at a very late stage. Huge opportunity to prevent liver-related death with community hepatitis B test and treat programmes. #hepsky #idsky
www.thelancet.com/journals/lan...
There is substantial heterogeneity in the contributors to the pathophysiology of #MASLD, which might influence its rate of progression, its relationship with #cardiometabolic diseases, and the response to therapy www.thelancet.com/journals/lan...
#OpenAccess
#MedSky #EndoSky #LiverSky #HepSky
